Oliver Fuhrmann, Ph.D.

Oliver (Oli) Fuhrmann leads Parexel´s Early Phase and Clinical Pharmacology business spanning the company’s owned Early Phase units, joint ventures and partner sites conducting Phase I-II programs for our Biotech and large pharma customers. Oli is responsible for the growth and profitability of this business segment and is the Executive Sponsor for several large pharma and Biotech customers in Europe.

With more than 23 years of experience across strategic management, customer relationship management and operational study delivery, Oli has served in several leadership roles at Parexel, including Executive Vice President and Global Head, Enterprise Account Group; Corporate Vice President, Enterprise Accounts Group and Emerging Accounts; Vice President, Early Phase Strategic Partnerships; and Head of Operations, Early Phase, Europe. A natural leader of growth-oriented, successful and sophisticated teams, Oli’s track record highlights excellent results in leadership and customer engagement activities.

Prior to joining Parexel, Oli was a Research Fellow at the Charité Hospital, Humboldt University, Berlin. He holds a Ph.D. in Molecular Biology from Humboldt University of Berlin.